Video

Aaron Boster from OhioHealth: Extended Data On Lemtrada Shows More Good News

Author(s):

As more and more treatments are approved for patients with multiple sclerosis questions are being answered about their effectiveness long past their approval dates. This is true for many of the medications including lemtrada.

As more and more treatments are approved for patients with multiple sclerosis questions are being answered about their effectiveness long past their approval dates. This is true for many of the medications including Lemtrada.

Aaron Boster, MD, from OhioHealth discussed the latest data being presented on the medication at the annual ECTRIMS conference in London. Unlike other treatments which are taken daily, weekly, or monthly Boster noted Lemtrada is given in much more extended durations and has shown to be effective for much longer periods of time. Many patients, he noted, do not need any further treatment after a second dose of the medication.

Related Videos
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
© 2024 MJH Life Sciences

All rights reserved.